Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Autoimmune Disorders

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 190 articles:
HTML format



Single Articles


    November 2022
  1. ZIEMSSEN T
    Reader Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use.
    Neurology. 2022;99:868.
    PubMed    


  2. PARNETTI L, Gaetani L
    Author Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use.
    Neurology. 2022;99:869.
    PubMed    


  3. DEERHAKE ME, Giarraputo J, Gupta M, Eckstein C, et al
    Journal Club: Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
    Neurology. 2022;99:854-857.
    PubMed    


  4. LEWIS A, Galetta S
    Editors' Note: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022;99:818.
    PubMed    


  5. BEBO BF
    Author Response: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022;99:819.
    PubMed    


  6. VARGAS WS
    Reader Response: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022;99:818-819.
    PubMed    


    October 2022
  7. LI L, Avina-Zubieta JA, Bernstein CN, Kaplan GG, et al
    Risk of Multiple Sclerosis Among Users of Antitumor Necrosis Factor Alpha in Four Canadian Provinces: A Population-Based Study.
    Neurology. 2022 Oct 28. pii: WNL.0000000000201472.
    PubMed     Abstract available



  8. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
    Neurology. 2022 Oct 28. pii: WNL.0000000000201391.
    PubMed    


  9. STRIJBIS EMM, Koch MW
    TNF Alfa Blockers and the Risk of Multiple Sclerosis.
    Neurology. 2022 Oct 28. pii: WNL.0000000000201629.
    PubMed    


  10. DOBSON R, Bove R
    In Vitro Fertilization and Multiple Sclerosis: Evolving Treatments and Reducing Relapse Risk.
    Neurology. 2022;99:737-738.
    PubMed    


  11. BRIL V, Szczudlik A, Vaitkus A, Rozsa C, et al
    A Randomized, Double-Blind, Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis.
    Neurology. 2022 Oct 21. pii: WNL.0000000000201501.
    PubMed     Abstract available


  12. DUBESSY AL, Stankoff B, Arnulf I
    Author Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2022;99:727.
    PubMed    


  13. SIEGLER JE, Galetta S
    Editors' Note: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2022;99:726.
    PubMed    


  14. SPARASCI D, Zecca C, Gobbi C, Manconi M, et al
    Reader Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2022;99:726-727.
    PubMed    


  15. SNETSELAAR L, Cheek JJ, Fox SS, Healy HS, et al
    Efficacy of Diet on Fatigue and Quality of Life in Multiple Sclerosis: A Systematic Review and Network Meta-analysis of Randomized Trials.
    Neurology. 2022 Oct 18. pii: WNL.0000000000201371.
    PubMed     Abstract available


  16. SPAIN R, Piccio L, Langer-Gould AM
    The Role of Diet in Multiple Sclerosis: Food for Thought.
    Neurology. 2022 Oct 18. pii: WNL.0000000000201565.
    PubMed    


  17. MURPHY OC, Calabresi PA, Gold DR
    Teaching Video NeuroImage: Dramatic Response to Topiramate in Acquired Pendular Nystagmus From Multiple Sclerosis.
    Neurology. 2022 Oct 11. pii: WNL.0000000000201452.
    PubMed    


  18. GANESH A, Galetta S
    Editors' Note: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022;99:630.
    PubMed    


  19. BARRO C
    Reader Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022;99:630-631.
    PubMed    


  20. LEPPERT D, Kropshofer H, Haring D, Dahlke F, et al
    Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022;99:631.
    PubMed    


  21. CORTESE R, Carrasco FP, Tur C, Bianchi A, et al
    Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.
    Neurology. 2022 Oct 3. pii: WNL.0000000000201465.
    PubMed     Abstract available


    September 2022
  22. BAARS AE, Kuitwaard K, de Koning LC, Luijten LWG, et al
    SARS-CoV-2 Vaccination Safety in Guillain-Barre Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropath.
    Neurology. 2022 Sep 20. pii: WNL.0000000000201376.
    PubMed     Abstract available


  23. ALLEN JA
    SARS-CoV-2 Vaccination and Autoimmune Neuropathies: Rebalancing the Risk.
    Neurology. 2022 Sep 20. pii: WNL.0000000000201366.
    PubMed    


  24. COTE-OROZCO JE, Velez-Tirado N
    Teaching NeuroImage: Hypothalamic Involvement in Neuromyelitis Optica Spectrum Disorder in a Child.
    Neurology. 2022;99:535-536.
    PubMed    


  25. GANESH A, Galetta S
    Editors' Note: Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
    Neurology. 2022;99:489.
    PubMed    


  26. VALE S
    Reader Response: Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
    Neurology. 2022;99:491.
    PubMed    


  27. GUASP M, Dalmau J
    Author Response: Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
    Neurology. 2022;99:490.
    PubMed    


  28. JEANTIN L, Plu I, Amador MDM, Maillart E, et al
    Pearls & Oy-sters: Spinal Cord Candidiasis Linked to CARD9 Deficiency Masquerading as a Longitudinally Extensive Transverse Myelitis.
    Neurology. 2022;99:475-479.
    PubMed     Abstract available


  29. CAROTENUTO A, Valsasina P, Schoonheim MM, Geurts JJ, et al
    Investigating Functional Network Abnormalities and Associations With Disability in Multiple Sclerosis.
    Neurology. 2022 Sep 12. pii: WNL.0000000000201264.
    PubMed     Abstract available


    August 2022
  30. CORDANO C, Nourbakhsh B, Yiu HH, Papinutto N, et al
    Differences in Age-Related Retinal and Cortical Atrophy Rates in Multiple Sclerosis.
    Neurology. 2022 Aug 29. pii: WNL.0000000000200977.
    PubMed     Abstract available


  31. VILLOSLADA P, Llufriu S
    Preventing Neurodegeneration in Multiple Sclerosis Is Required From the Earliest Stages of the Disease.
    Neurology. 2022 Aug 29. pii: WNL.0000000000201223.
    PubMed    


  32. HWANG S, Garcia-Dominguez MA, Fitzgerald KC, Saylor DR, et al
    Association of Multiple Sclerosis Prevalence With Sociodemographic, Health Systems, and Lifestyle Factors on a National and Regional Level.
    Neurology. 2022 Aug 24. pii: WNL.0000000000200962.
    PubMed     Abstract available


  33. LOPEZ-JIMENEZ A, Gutierrez-Gutierrez G, Guerra-Hiraldo JD, Kurtis MM, et al
    Teaching Video NeuroImage: Hung-Up Reflex in Stiff Limb Syndrome.
    Neurology. 2022;99:356.
    PubMed    


  34. SHAH SS, Morris P, Buciuc M, Tajfirouz D, et al
    Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD.
    Neurology. 2022;99:e851-e857.
    PubMed     Abstract available


  35. BRENTON JN, Florenzo B, Koshiya H, Min S, et al
    Six-Minute Walk as a Measure of Walking Capacity and Endurance in Patients With Pediatric-Onset Multiple Sclerosis.
    Neurology. 2022 Aug 19. pii: WNL.0000000000201098.
    PubMed     Abstract available


  36. LEONHARD SE, van der Eijk AA, Andersen H, Antonini G, et al
    An International Perspective on Preceding Infections in Guillain-Barre Syndrome: The IGOS-1000 Cohort.
    Neurology. 2022 Aug 18. pii: WNL.0000000000200885.
    PubMed     Abstract available


  37. ROOS I, Malpas C, Leray E, Casey R, et al
    Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2022 Aug 17. pii: WNL.0000000000201029.
    PubMed     Abstract available


  38. MCLAREN JR, Mitchell MK, Al-Maadid FM, Staley KJ, et al
    Clinical Reasoning: An 8-Year-Old With Acute Onset Ataxia.
    Neurology. 2022;99:305-310.
    PubMed     Abstract available


  39. DOBSON R, Bove R
    IVF and Multiple Sclerosis: Evolving Treatments and Reducing Relapse Risk.
    Neurology. 2022 Aug 11. pii: WNL.0000000000201242.
    PubMed    


  40. MAINGUY M, Tillaut H, Degremont A, Le Page E, et al
    Assessing the Risk of Relapse Requiring Corticosteroids After In Vitro Fertilization in Women With Multiple Sclerosis.
    Neurology. 2022 Aug 11. pii: WNL.0000000000201027.
    PubMed     Abstract available


  41. O'MAHONY J, Salter A, Ciftci B, Fox RJ, et al
    Physical and Mental Health-Related Quality of Life Trajectories Among People With Multiple Sclerosis.
    Neurology. 2022 Aug 10. pii: WNL.0000000000200931.
    PubMed     Abstract available


  42. SECHI E, Gallus E, Solla P, Puggioni D, et al
    Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis.
    Neurology. 2022;99:256-257.
    PubMed    


  43. PIAZZA F, Caminiti SP, Zedde M, Presotto L, et al
    Association of Microglial Activation With Spontaneous ARIA-E and Cerebrospinal Fluid Levels of Anti-A Autoantibodies.
    Neurology. 2022 Aug 8. pii: WNL.0000000000200892.
    PubMed     Abstract available


  44. BSTEH G, Krajnc N, Riedl K, Altmann P, et al
    Retinal Layer Thinning After Optic Neuritis is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis.
    Neurology. 2022 Aug 2. pii: WNL.0000000000200970.
    PubMed     Abstract available


    July 2022
  45. KUANG SY, Li Y, Yang SL, Han X, et al
    Child Neurology: Aicardi-Goutieres Syndrome Presenting as Recurrent Ischemic Stroke.
    Neurology. 2022 Jul 8. pii: WNL.0000000000200952.
    PubMed     Abstract available


    June 2022
  46. KENNEY RC, Liu M, Hasanaj L, Joseph B, et al
    The Role of OCT Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis.
    Neurology. 2022 Jun 28. pii: WNL.0000000000200883.
    PubMed     Abstract available


  47. TOOSY AT, Eshaghi A
    Machine Learning Utility for Optical Coherence Tomography in Multiple Sclerosis: Is the Future Now?
    Neurology. 2022 Jun 28. pii: WNL.0000000000200862.
    PubMed    


  48. FREEDMAN MS, Pozzilli C, Havrdova EK, Lemle A, et al
    Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results from Randomized Phase 2b Core and Extension Studies.
    Neurology. 2022 Jun 6. pii: WNL.0000000000200606.
    PubMed     Abstract available


    May 2022
  49. SOTIRCHOS ES, Vasileiou ES, Filippatou AG, Fitzgerald KC, et al
    Association of Serum Neurofilament Light Chain With Inner Retinal Layer Thinning in Multiple Sclerosis.
    Neurology. 2022 May 26. pii: WNL.0000000000200778.
    PubMed     Abstract available


  50. GRAVES J
    Identifying Multiple Sclerosis Activity: Do the Eyes Have It?
    Neurology. 2022 May 26. pii: WNL.0000000000200903.
    PubMed    


  51. YANG JH, Graves JS
    Cancer Screening in Patients With Multiple Sclerosis: Are We Doing Enough?
    Neurology. 2022;98:737-738.
    PubMed    


  52. LANGER-GOULD AM, Gonzales EG, Smith JB, Li BH, et al
    Racial and Ethnic Disparities in Multiple Sclerosis Prevalence.
    Neurology. 2022;98:e1818-e1827.
    PubMed     Abstract available


  53. GROOME PA, Webber C, Maxwell CJ, McClintock C, et al
    Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer.
    Neurology. 2022;98:e1798-e1809.
    PubMed     Abstract available


    April 2022
  54. WU Q, Zhao CW, Dai S
    Teaching Video NeuroImage: Generalized Reflex Myoclonus in Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome.
    Neurology. 2022 Apr 29. pii: WNL.0000000000200733.
    PubMed    


  55. YANG JH, Graves JS
    Cancer Screening in Patients With Multiple Sclerosis: Are We Doing Enough?
    Neurology. 2022 Apr 28. pii: WNL.0000000000200366.
    PubMed    


  56. HAMILTON R, Ciccarelli O
    Multiple Sclerosis Incidence in Black Patients: It's Time to Do Away With a Racial Medical Myth.
    Neurology. 2022 Apr 28. pii: WNL.0000000000200309.
    PubMed    


  57. LANGER-GOULD AM, Gonzales EG, Smith JB, Li BH, et al
    Racial and Ethnic Disparities in Multiple Sclerosis Prevalence.
    Neurology. 2022 Apr 28. pii: WNL.0000000000200151.
    PubMed     Abstract available


  58. GROOME PA, Webber C, Maxwell CJ, McClintock C, et al
    Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer.
    Neurology. 2022 Apr 28. pii: WNL.0000000000200163.
    PubMed     Abstract available


  59. ROTSTEIN D, Solomon JM, Sormani MP, Montalban X, et al
    Association of No Evidence of Disease Activity With No Long-term Disability Progression in Multiple Sclerosis: A Systematic Review and Meta-analysis.
    Neurology. 2022 Apr 26. pii: WNL.0000000000200549.
    PubMed     Abstract available


  60. OKAI AF, Howard AM, Williams MJ, Brink JD, et al
    Advancing Care and Outcomes for African American Patients With Multiple Sclerosis.
    Neurology. 2022 Apr 25. pii: WNL.0000000000200791.
    PubMed     Abstract available


  61. PORTACCIO E, Bellinvia A, Razzolini L, Pasto L, et al
    Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.
    Neurology. 2022;98:e1626-e1636.
    PubMed     Abstract available


  62. SWART G, Balgobind S, Chan C, Fulham M, et al
    Spinal Cord Presentation of Biopsy-Proven PET-Positive Giant Cell Arteritis.
    Neurology. 2022 Apr 15. pii: WNL.0000000000200749.
    PubMed     Abstract available


  63. BEBO B, Cintina I, LaRocca N, Ritter L, et al
    Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022 Apr 13. pii: WNL.0000000000200150.
    PubMed     Abstract available


  64. OSTKAMP P, Schwab N
    Effects of Latitude and Sunlight on Multiple Sclerosis Severity: Two Peas in a Pod?
    Neurology. 2022 Apr 11. pii: WNL.0000000000200105.
    PubMed    


  65. VITKOVA M, Diouf I, Malpas C, Horakova D, et al
    Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study.
    Neurology. 2022 Apr 11. pii: WNL.0000000000200545.
    PubMed     Abstract available


  66. GUASP M, Martin-Aguilar L, Sabater L, Bioque M, et al
    Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis.
    Neurology. 2022;98:e1489-e1498.
    PubMed     Abstract available


  67. LEPPERT D, Kropshofer H, Haring DAA, Dahlke F, et al
    Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022 Apr 4. pii: WNL.0000000000200258.
    PubMed     Abstract available


    March 2022
  68. GALLAY L, Fermon C, Lessard L, Weiss-Gayet M, et al
    Involvement of Type-I Interferon Signaling in Muscle Stem Cell Proliferation During Dermatomyositis.
    Neurology. 2022 Mar 29. pii: WNL.0000000000200271.
    PubMed     Abstract available


  69. PINAL-FERNANDEZ I, Greenberg SA
    Type I Interferons in Dermatomyositis Myoblasts: Toxic Effect and a Potential Autocrine Loop.
    Neurology. 2022 Mar 29. pii: WNL.0000000000200679.
    PubMed    


  70. BOURDETTE D, Sormani MP
    Thinking Anew: Accelerating Clinical Trials of New Therapies for Progressive Multiple Sclerosis.
    Neurology. 2022 Mar 23. pii: WNL.0000000000200597.
    PubMed    


  71. LI V, Leurent B, Barkhof F, Braisher M, et al
    Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis.
    Neurology. 2022 Mar 23. pii: WNL.0000000000200604.
    PubMed     Abstract available


  72. MOLIMARD A, Gitiaux C, Barnerias C, Audic F, et al
    Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis: The French Experience.
    Neurology. 2022 Mar 21. pii: WNL.0000000000200288.
    PubMed     Abstract available


  73. BRIDEL C, Killestein J, Teunissen C
    Author Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2022;98:471.
    PubMed    


  74. KROPSHOFER H, Haring DA, Kappos L, Leppert D, et al
    Reader Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2022;98:470-471.
    PubMed    


  75. LEWIS A, Galetta S
    Editors' Note: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2022;98:470.
    PubMed    


  76. HUMMERT MW, Schoppe LM, Bellmann-Strobl J, Siebert N, et al
    Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCE(NMO) Study.
    Neurology. 2022;98:e1184-e1196.
    PubMed     Abstract available


  77. SIMMONS SB, Ontaneda D
    Slowly Expanding Lesions: A New Target for Progressive Multiple Sclerosis Trials?
    Neurology. 2022 Mar 11. pii: WNL.0000000000200230.
    PubMed    


  78. AZZOLINI F, Farina A, Gastaldi M, Barilaro A, et al
    Leptomeningeal Gadolinium Enhancement in Autoimmune GFAP-Astrocytopathy.
    Neurology. 2022 Mar 11. pii: WNL.0000000000200291.
    PubMed    


  79. CALVI A, Carrasco FP, Tur C, Chard DT, et al
    Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis.
    Neurology. 2022 Mar 11. pii: WNL.0000000000200144.
    PubMed     Abstract available


  80. ZENG YH, Zhao M, Guo XX, Wang N, et al
    Cutaneous Lesions as a Clue to the Etiology of Extensive Intracranial Calcifications: Aicardi-Goutieres Syndrome.
    Neurology. 2022;98:417-418.
    PubMed    


  81. LEVISON LS, Thomsen RW, Sindrup SH, Andersen H, et al
    Association Between Incident Cancer and Guillain-Barre Syndrome Development: A Nationwide Case-Control Study.
    Neurology. 2022 Mar 2. pii: WNL.0000000000200015.
    PubMed     Abstract available


  82. HAMILTON RH, Ciccarelli O
    Non-White Participants Matter in White Matter Disease Studies: The Importance of Diversity in Multiple Sclerosis Clinical Trials.
    Neurology. 2022;98:345-346.
    PubMed    


    February 2022
  83. MARZOUGHI S, Marulanda L, Ngo D, Chen T, et al
    Pearls & Oy-sters: Delayed Diagnosis of Acute Motor Axonal Neuropathy With Cardiac Arrest.
    Neurology. 2022;98:336-339.
    PubMed    


  84. LIE IA, Weeda MM, Mattiesing RM, Mol MAE, et al
    Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis: A Systematic Review.
    Neurology. 2022 Feb 16. pii: WNL.0000000000200006.
    PubMed     Abstract available


  85. MCELWEE DECKER B, Thibault D, Davis KA, Willis AW, et al
    Population-Based Study of Nonelective Postpartum Readmissions in Women With Stroke, Migraine, Multiple Sclerosis, and Myasthenia Gravis.
    Neurology. 2022 Feb 15. pii: WNL.0000000000200007.
    PubMed     Abstract available


  86. HACOHEN Y, Ciccarelli O
    New Evidence for EBV Infection as a Cause of Multiple Sclerosis.
    Neurology. 2022 Feb 10. pii: WNL.0000000000200243.
    PubMed    


  87. MAMMEN AL
    Inclusion Body Myositis: An Autoimmune or Myodegenerative Disease?
    Neurology. 2022 Feb 7. pii: WNL.0000000000200188.
    PubMed    


  88. TORTORELLA C, Aiello A, Gasperini C, Agrati C, et al
    Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
    Neurology. 2022;98:e541-e554.
    PubMed     Abstract available


    January 2022
  89. ONUORAH HM, Charron O, Meltzer E, Montague A, et al
    Enrollment of Non-White Participants and Reporting of Race and Ethnicity in Phase III Trials of Multiple Sclerosis DMTs: A Systematic Review.
    Neurology. 2022 Jan 19. pii: WNL.0000000000013230.
    PubMed     Abstract available


  90. CUTTER GR, Koch MW
    Multiple Sclerosis Diagnostic Criteria: Moving Ahead or Walking in Place?
    Neurology. 2022;98:12-13.
    PubMed    


  91. FILIPPI M, Preziosa P, Meani A, Dalla Costa G, et al
    Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study.
    Neurology. 2022;98:e1-e14.
    PubMed     Abstract available


    December 2021
  92. DOETS AY, Lingsma HF, Walgaard C, Islam B, et al
    Predicting Outcome in Guillain-Barre Syndrome: International Validation of the Modified Erasmus GBS Outcome Score.
    Neurology. 2021 Dec 22. pii: WNL.0000000000013139.
    PubMed     Abstract available


  93. MIRZA AI, Zhu F, Knox N, Forbes JD, et al
    Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome.
    Neurology. 2021 Dec 22. pii: WNL.0000000000013245.
    PubMed     Abstract available


  94. COSTA AF, Rodriguez A, Martinez P, Blanco DCM, et al
    Teaching Video NeuroImage: Uncommon Neuro-ophthalmic Finding in a Patient With Miller Fisher Syndrome and Past SARS-CoV-2 Infection.
    Neurology. 2021;97:e2431-e2432.
    PubMed    


  95. SHELLY S, Klein CJ, Dyck PJB, Paul P, et al
    Neurofascin-155 Immunoglobulin Subtypes: Clinicopathologic Associations and Neurologic Outcomes.
    Neurology. 2021;97:e2392-e2403.
    PubMed     Abstract available


  96. SEBASTIAN P, Cherbuin N, Barcellos LF, Roalstad S, et al
    Association Between Time Spent Outdoors and Risk of Multiple Sclerosis.
    Neurology. 2021 Dec 8. pii: WNL.0000000000013045.
    PubMed     Abstract available


  97. GRAVES JS, Killestein J
    Reading the "T" Leaves of COVID-19 Vaccine Responses in Multiple Sclerosis.
    Neurology. 2021 Dec 8. pii: WNL.0000000000013166.
    PubMed    


  98. TANBOON J, Inoue M, Saito Y, Tachimori H, et al
    Dermatomyositis: Muscle Pathology According to Antibody Subtypes.
    Neurology. 2021 Dec 6. pii: WNL.0000000000013176.
    PubMed     Abstract available


  99. NOWAK RJ, Coffey CS, Goldstein JM, Dimachkie MM, et al
    Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.
    Neurology. 2021 Dec 2. pii: WNL.0000000000013121.
    PubMed     Abstract available


    November 2021
  100. NEUPERT DG, Rathke KM, Mikati MA
    Teaching Video NeuroImage: Hereditary Hyperekplexia Mimicking Tonic Seizures in an Infant.
    Neurology. 2021;97:e2248-e2249.
    PubMed     Abstract available


  101. TENCER J, Yum SW
    Teaching NeuroImage: Basal Ganglia T1 Hyperintensity and SWI Signal Diabetic Striatopathy in an 18-Year-Old Man With Type 1 Diabetes Mellitus.
    Neurology. 2021;97:e2148-e2149.
    PubMed    


  102. DUMONCEAU AG, Ameli R, Rogemond V, Ruiz A, et al
    Glial Fibrillary Acidic Protein Autoimmunity: A French Cohort Study.
    Neurology. 2021 Nov 19. pii: WNL.0000000000013087.
    PubMed     Abstract available


    October 2021

  103. Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG Study.
    Neurology. 2021 Oct 29. pii: WNL.0000000000013021.
    PubMed    


  104. AMATO A
    Author Response: Guillain-Barre Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial.
    Neurology. 2021;97:841-842.
    PubMed    


  105. WILLER J
    Reader Response: Guillain-Barre Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial.
    Neurology. 2021;97:841.
    PubMed    


  106. TINTORE M, Cobo-Calvo A, Carbonell P, Arrambide G, et al
    Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome.
    Neurology. 2021;97:e1641-e1652.
    PubMed     Abstract available


  107. AA HOGLUND RA, Meyer HE, Stigum H, Torkildsen O, et al
    Association of Body Mass Index in Adolescence and Young Adulthood and Long-term Risk of Multiple Sclerosis: A Population-Based Study.
    Neurology. 2021 Oct 25. pii: WNL.0000000000012957.
    PubMed     Abstract available


  108. KALINCIK T, Tremlett H, Ascherio A
    High BMI In Youths as a Modifiable Risk Factor for Multiple Sclerosis: Weighing Up the Evidence.
    Neurology. 2021 Oct 25. pii: WNL.0000000000012966.
    PubMed    


  109. AGHAJAN Y, Mitchell RN, Bhattacharyya S, Hsu TY, et al
    Teaching NeuroImage: Bilateral Middle Cerebellar Peduncle Stroke in Giant Cell Arteritis.
    Neurology. 2021 Oct 19. pii: WNL.0000000000012953.
    PubMed    


  110. JANDRIC D, Lipp I, Paling D, Rog D, et al
    Mechanisms of Network Changes in Cognitive Impairment in Multiple Sclerosis.
    Neurology. 2021 Oct 14. pii: WNL.0000000000012834.
    PubMed     Abstract available


  111. SANCHEZ CV, Theel E, Binnicker M, Toledano M, et al
    Autoimmune Encephalitis Post-SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes.
    Neurology. 2021 Oct 11. pii: WNL.0000000000012931.
    PubMed     Abstract available


  112. SIMPSON-YAP S, De Brouwer E, Kalincik T, Rijke N, et al
    Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Neurology. 2021 Oct 5. pii: WNL.0000000000012753.
    PubMed     Abstract available


  113. KILLESTEIN J, Schoonheim MM, Voskuhl RR
    B-Cell Depletion and COVID-19 Severity in Multiple Sclerosis: Remaining Challenges.
    Neurology. 2021 Oct 5. pii: WNL.0000000000012754.
    PubMed    


  114. BONACCHI R, Meani A, Pagani E, Marchesi O, et al
    Association of Age at Onset With Gray Matter Volume and White Matter Microstructural Abnormalities in People With Multiple Sclerosis.
    Neurology. 2021 Oct 4. pii: WNL.0000000000012869.
    PubMed     Abstract available


  115. HACOHEN Y, Eshaghi A
    Multiple Sclerosis in Children and Adults: Does Age Matter?
    Neurology. 2021 Oct 4. pii: WNL.0000000000012866.
    PubMed    


  116. VRENKEN H, Jenkinson M, Pham D, Guttmann CRG, et al
    Opportunities for Understanding MS Mechanisms and Progression With MRI Using Large-Scale Data Sharing and Artificial Intelligence.
    Neurology. 2021 Oct 4. pii: WNL.0000000000012884.
    PubMed     Abstract available


    September 2021
  117. ZHAO-FLEMING HH, Valencia Sanchez C, Sechi E, Inbarasu J, et al
    CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies.
    Neurology. 2021;97:e1351-e1358.
    PubMed     Abstract available


  118. MERLO D, Stankovich J, Bai C, Kalincik T, et al
    Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2021 Sep 23. pii: WNL.0000000000012850.
    PubMed     Abstract available


  119. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
    Colorectal Cancer Survival in Multiple Sclerosis: A Matched Cohort Study.
    Neurology. 2021 Sep 15. pii: WNL.0000000000012634.
    PubMed     Abstract available


  120. TOBIN O
    Early Diagnosis and Treatment is Associated With Improved Outcomes in Patients With Multiple Sclerosis.
    Neurology. 2021 Sep 14. pii: WNL.0000000000012738.
    PubMed    


  121. CAMELO-FILHO AE, Estephan EP, Heise CO, Zanoteli E, et al
    Teaching Video NeuroImage: Reflex Facilitation in Lambert-Eaton Myasthenic Syndrome.
    Neurology. 2021;97:e1168-e1169.
    PubMed    


  122. MILLER JW
    Inflammation As A Target For Epilepsy Therapy: The Case of Natalizumab.
    Neurology. 2021 Sep 14. pii: WNL.0000000000012768.
    PubMed    


  123. GOLDSCHMIDT C, Fox RJ
    Relationship Between Serum Neurofilament Light and Multiple Sclerosis Disability Progression: Clear as Mud.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012755.
    PubMed    


  124. TOBIN WO, Kalinowska-Lyszczarz A, Weigand SD, Guo Y, et al
    Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012782.
    PubMed     Abstract available


  125. BRIDEL C, Leurs CE, van Lierop ZY, van Kempen ZL, et al
    Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012752.
    PubMed     Abstract available


  126. RADCLIFFE C, Potnis K, Peng TJ, DeCroce-Movson E, et al
    Teaching NeuroImage: Papilledema and Pachymeningitis: An Atypical Presentation of Granulomatosis With Polyangiitis.
    Neurology. 2021;97:e1060-e1061.
    PubMed    


  127. YEH EA, Bourdette D, Wiendl H
    Longer-Term Safety of B-Cell Therapy With Ocrelizumab in Multiple Sclerosis.
    Neurology. 2021 Sep 2. pii: WNL.0000000000012716.
    PubMed    


  128. HAUSER SL, Kappos L, Montalban X, Craveiro L, et al
    Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.
    Neurology. 2021 Sep 2. pii: WNL.0000000000012700.
    PubMed     Abstract available


  129. PALLADINO R, Chataway J, Majeed A, Marrie RA, et al
    Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality: A Population-Based Matched Cohort Study.
    Neurology. 2021 Sep 1. pii: WNL.0000000000012610.
    PubMed     Abstract available


  130. SALTER A
    Assessment of Biological Interactions Between MS Status and Depression for Mortality.
    Neurology. 2021 Sep 1. pii: WNL.0000000000012615.
    PubMed    


    August 2021
  131. RICE J, Xiang XM
    Comparing the Effectiveness of Therapies in People With Secondary Progressive Multiple Sclerosis.
    Neurology. 2021;97:e972-e974.
    PubMed    


  132. DOBSON R, Salter A
    Differing Impact of Disease-Modifying Therapy on Relapse and Progression: Time to Consider Inflammation and Neuroprotection Separately?
    Neurology. 2021;97:407-408.
    PubMed    


  133. KOCH MW, Mostert JP, Wolinsky JS, Lublin FD, et al
    Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2021 Aug 25. pii: WNL.0000000000012690.
    PubMed     Abstract available


  134. PETERSSON M, Feresiadou A, Jons D, Ilinca A, et al
    Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG Study.
    Neurology. 2021 Aug 10. pii: WNL.0000000000012604.
    PubMed     Abstract available


  135. KOCH MW, Mostert J, Zhang Y, Wolinsky JS, et al
    Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.
    Neurology. 2021 Aug 10. pii: WNL.0000000000012603.
    PubMed     Abstract available


  136. FREY J, Kramer J, Castellani R, Sriwastava S, et al
    Clinical Reasoning: A 47-Year-Old With Headache, Vertigo, and Double Vision.
    Neurology. 2021;97:e535-e539.
    PubMed    


  137. STRUPP M, Frenzel C, Goldschagg N, Halmagyi GM, et al
    Teaching Video NeuroImage: One Bedside Test, 2 Clinical Signs: One Vestibular, the Other Ocular Motor.
    Neurology. 2021;97:e541-e542.
    PubMed    


    July 2021
  138. KARCESKI S
    Myasthenia Gravis: Which Type of Surgery Is Best?
    Neurology. 2021;97:e433-e435.
    PubMed    


  139. CHEN T
    Clinical Reasoning: A 68-Year-Old Man With Proximal Weakness and Seizures.
    Neurology. 2021;97:e423-e428.
    PubMed    


  140. SECHI E, Krecke KN, Messina SA, Buciuc M, et al
    Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.
    Neurology. 2021 Jul 14. pii: WNL.0000000000012467.
    PubMed     Abstract available


  141. RASMINSKY M
    GCA Squared.
    Neurology. 2021;97:90-91.
    PubMed    


  142. NICHOLAS RS, Rhone EE, Mariottini A, Silber E, et al
    Autologous Haematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: a Real-world Case Series.
    Neurology. 2021 Jul 12. pii: WNL.0000000000012449.
    PubMed     Abstract available


  143. LISAK RP
    [Editorial] At the Junction Where It Happens: Antibodies to LRP4 and Agrin Are Pathogenic in Myasthenia Gravis [re: M/S #2020/169756].
    Neurology. 2021 Jul 7. pii: WNL.0000000000012471.
    PubMed    


  144. YU Z, Zhang M, Jing H, Chen P, et al
    Characterization of LRP4/Agrin Antibodies From a Patient with Myasthenia Gravis.
    Neurology. 2021 Jul 7. pii: WNL.0000000000012463.
    PubMed     Abstract available


  145. HACOHEN Y, Kerr W, Waters P
    Intrathecal Production of MOG-IgG: Highlighting the Need for CSF Testing in Clinical Practice.
    Neurology. 2021;97:12-13.
    PubMed    


  146. AKAISHI T, Takahashi T, Misu T, Kaneko K, et al
    Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2021;97:e1-e12.
    PubMed     Abstract available


  147. GUASP M, Gine-Serven E, Maudes E, Rosa-Justicia M, et al
    Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis.
    Neurology. 2021;97:e61-e75.
    PubMed     Abstract available


    June 2021
  148. GRAY-RONCAL K, Fitzgerald K, Ryerson LZ, Charvet L, et al
    Association of Disease Severity and Socioeconomic Status in Black and White Americans With Multiple Sclerosis.
    Neurology. 2021 Jun 30. pii: WNL.0000000000012362.
    PubMed     Abstract available


  149. ROOS I, Leray E, Casey R, Horakova D, et al
    Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis.
    Neurology. 2021 Jun 30. pii: WNL.0000000000012354.
    PubMed     Abstract available


  150. MYERS KA
    Author Response: Teaching Video NeuroImages: Pathologic Yawning: A Sign of Brainstem Involvement in Acute Disseminated Encephalomyelitis?
    Neurology. 2021;96:1105.
    PubMed    


  151. FUJIMORI J, Nakashima I
    Reader Response: Teaching Video NeuroImages: Pathologic Yawning: A Sign of Brainstem Involvement in Acute Disseminated Encephalomyelitis?
    Neurology. 2021;96:1104-1105.
    PubMed    


  152. VILLACIEROS-ALVAREZ J, Ordas CM, Torres-Gaona G, Diez-Barrio A, et al
    Teaching Video NeuroImages: Anti-IgLON5 Disease: A Long-Course Presentation With a Response to Immunotherapy.
    Neurology. 2021;96:e2901-e2902.
    PubMed    


  153. HUISKAMP M, Eijlers AJC, Broeders TAA, Pasteuning J, et al
    Longitudinal Network Changes and Conversion to Cognitive Impairment in Multiple Sclerosis.
    Neurology. 2021 Jun 7. pii: WNL.0000000000012341.
    PubMed     Abstract available


  154. PREZIOSA P, Schoonheim MM
    Ongoing Axonal Injury in Chronic Active Lesions in Multiple Sclerosis: In-Vivo Quantification Using Serum Neurofilament.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012331.
    PubMed    


  155. CAMPBELL CREE BA, Arnold DL, Chataway J, Chitnis T, et al
    Secondary Progressive Multiple Sclerosis: New Insights.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012323.
    PubMed     Abstract available


  156. MAGGI P, Kuhle J, Schadelin S, van der Meer F, et al
    Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012326.
    PubMed     Abstract available


    May 2021
  157. SAN MARTIN AH, Cuadrado CA, Arbizu MG, Rabano-Suarez P, et al
    Autoimmune Septin-5 Disease Presenting as Spinocerebellar Ataxia and Nystagmus.
    Neurology. 2021 May 24. pii: WNL.0000000000012240.
    PubMed    


  158. ROLLOT F, Fauvernier M, Uhry Z, Vukusic S, et al
    Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort.
    Neurology. 2021 May 19. pii: WNL.0000000000012224.
    PubMed     Abstract available


  159. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
    Breast Cancer Survival in Multiple Sclerosis: A Matched Cohort Study.
    Neurology. 2021 May 19. pii: WNL.0000000000012127.
    PubMed     Abstract available


  160. JOLLIFFE EA, Guo Y, Hardy TA, Morris PP, et al
    Clinical and Radiologic Features, Pathology, and Treatment of Balo Concentric Sclerosis.
    Neurology. 2021 May 19. pii: WNL.0000000000012230.
    PubMed     Abstract available


  161. TOOSY AT, Kapur K, Nair KV
    Is OCT a Viable Tool to Monitor Disease-Modifying Treatments in RRMS Yet?
    Neurology. 2021;96:927-928.
    PubMed    


  162. DAY GS, Yarbrough MY, Kortvelyessy P, Pruss H, et al
    Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis.
    Neurology. 2021;96:e2546-e2557.
    PubMed     Abstract available


  163. TITULAER MJ, Day GS
    Autoimmune Encephalitis in First Episode Psychoses: All Smoke and No Fire?
    Neurology. 2021 May 12. pii: WNL.0000000000012195.
    PubMed    


  164. GIANNOCCARO MP, Liguori R
    Author Response: Comparison of Ice Pack Test and Single-Fiber EMG Diagnostic Accuracy in Patients Referred for Myasthenic Ptosis.
    Neurology. 2021;96:918-919.
    PubMed    


  165. SILVESTRI N
    Reader Response: Comparison of Ice Pack Test and Single-Fiber EMG Diagnostic Accuracy in Patients Referred for Myasthenic Ptosis.
    Neurology. 2021;96:918.
    PubMed    


  166. NERSESJAN V, McWilliam O, Krarup LH, Kondziella D, et al
    Autoimmune Encephalitis Related to Cancer Treatment With Immune Checkpoint Inhibitors: Systematic Review.
    Neurology. 2021 May 5. pii: WNL.0000000000012122.
    PubMed     Abstract available



  167. Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
    Neurology. 2021 May 4. pii: WNL.0000000000011825.
    PubMed    


  168. SOLIS-PAZMINO P, Baiu I, Lincango-Naranjo E, Trope W, et al
    Impact of the Surgical Approach to Thymectomy Upon Complete Stable Remission Rates in Myasthenia Gravis: A Meta-analysis.
    Neurology. 2021 May 4. pii: WNL.0000000000012153.
    PubMed     Abstract available


  169. FOX RJ, Kryscio RJ
    A New Way to Identify Promising Therapies for Progressive Multiple Sclerosis.
    Neurology. 2021;96:833-834.
    PubMed    


  170. KOCH MW, Sage K, Kaur S, Kim J, et al
    Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial.
    Neurology. 2021;96:e2313-e2322.
    PubMed     Abstract available


  171. BAR-OR A, Herman A, Stokmaier D
    Author Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:870.
    PubMed    


  172. HAHN N
    Reader Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:870.
    PubMed    


  173. SIEGLER JE, Galetta S
    Editors' Note: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:869.
    PubMed    


    April 2021
  174. DUBESSY AL, Tezenas du Montcel S, Viala F, Assouad R, et al
    Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2021 Apr 30. pii: WNL.0000000000012120.
    PubMed     Abstract available


  175. ZOUVELOU V, Daponte A
    Teaching Video NeuroImages: Resolution of Ptosis After Forceful Eye Closure: Bedside Diagnosis of Myasthenia Gravis.
    Neurology. 2021 Apr 30. pii: WNL.0000000000012100.
    PubMed    


  176. LEAVITT VM, Dobson R, Svennigsson A
    Perinatal Depression and Anxiety in Multiple Sclerosis: Treatable Distress.
    Neurology. 2021 Apr 28. pii: WNL.0000000000012101.
    PubMed    


  177. SHELLY S, Mills JR, Dubey D, McKeon A, et al
    Clinical Utility of Striational Antibodies in Paraneoplastic and Myasthenia Gravis Paraneoplastic Panels.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012050.
    PubMed     Abstract available


  178. SALAVISA M, Serrazina F, Pires P, Correia AS, et al
    Teaching Video NeuroImages: Infratentorial Multiple Sclerosis Relapse Presenting as Continuous Hemifacial Myokymia.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012052.
    PubMed    


  179. GASPERI C, Hapfelmeier A, Daltrozzo T, Schneider A, et al
    Systematic Assessment of Medical Diagnoses Preceding the First Diagnosis of Multiple Sclerosis.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012074.
    PubMed     Abstract available


  180. SOLOMON AJ, Ascherio A
    Early Diagnosis of Multiple Sclerosis: Further Evidence for Missed Opportunity.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012087.
    PubMed    



  181. Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis.
    Neurology. 2021 Apr 23. pii: WNL.0000000000012021.
    PubMed    


  182. EID K, Torkildsen OF, Aarseth J, Flemmen HO, et al
    Perinatal Depression and Anxiety in Women with Multiple Sclerosis: A Population-Based Cohort Study.
    Neurology. 2021 Apr 21. pii: WNL.0000000000012062.
    PubMed     Abstract available


  183. YEH WZ, Widyastuti PA, Van der Walt A, Stankovich J, et al
    Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
    Neurology. 2021 Apr 20. pii: WNL.0000000000012084.
    PubMed     Abstract available


  184. SHELLY S, Shouman K, Paul P, Engelstad J, et al
    Expanding the Spectrum of Chronic Immune Sensory Polyradiculopathy: CISP-Plus.
    Neurology. 2021;96:e2078-e2089.
    PubMed     Abstract available


  185. NISHIDA H, Kohyama K, Kumada S, Takanashi JI, et al
    Evaluation of the Diagnostic Criteria for Anti-NMDA Receptor Encephalitis in Japanese Children.
    Neurology. 2021;96:e2070-e2077.
    PubMed     Abstract available


  186. COLLONGUES N, Alves Do Rego C, Bourre B, Biotti D, et al
    Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder.
    Neurology. 2021;96:e2006-e2015.
    PubMed     Abstract available


  187. LAMBE J, Risher H, Filippatou AG, Murphy OC, et al
    Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis.
    Neurology. 2021 Apr 7. pii: WNL.0000000000011933.
    PubMed     Abstract available


  188. BOURDETTE D, Killestein J
    Quelling Public Fears about Guillain-Barre Syndrome and COVID-19 Vaccination.
    Neurology. 2021 Apr 6. pii: WNL.0000000000011882.
    PubMed    


  189. MARQUEZ LOZA AM, Holroyd KB, Johnson SA, Pilgrim DM, et al
    Guillain- Barre Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial: Temporal Associations Do Not Imply Causality.
    Neurology. 2021 Apr 6. pii: WNL.0000000000011881.
    PubMed    


  190. ALLEN JA, Pasnoor M, Dimachkie MM, Ajroud-Driss S, et al
    Quantifying Treatment-Related Fluctuations in CIDP: Results of the GRIPPER Study.
    Neurology. 2021;96:e1876-e1886.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: